ASND · Ascendis Pharma A/S
United States · RS rating 34 · As of 2026-10-14
| Price | 227.00 USD |
|---|---|
| 1-day change | +1.7% |
| RS rating (overall / 1M / 3M / 12M) | 34 / 36 / 28 / 59 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 41 / 30 / 42 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +45.0% |
| Sales growth Q/Q | +15.8% |
| Distance from 52-week high | +18.1% |
| Market cap (USD) | $13.9B |